Vanguard Capital Wealth Advisors reduced its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,700 shares of the biotechnology company’s stock after selling 200 shares during the period. Vanguard Capital Wealth Advisors’ holdings in Sarepta Therapeutics were worth $512,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Cornerstone Advisors Inc. bought a new stake in Sarepta Therapeutics in the 3rd quarter worth approximately $25,000. First Quadrant L P CA bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $130,000. Ffcm LLC bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $162,000. Advisory Research Inc. bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $214,000. Finally, GWM Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at $221,000. Institutional investors own 90.93% of the company’s stock.
Shares of SRPT stock opened at $139.71 on Friday. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of -85.19 and a beta of 1.91. Sarepta Therapeutics Inc has a 52 week low of $50.68 and a 52 week high of $176.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 7.84 and a current ratio of 8.85.
SRPT has been the subject of a number of recent research reports. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Royal Bank of Canada reissued an “outperform” rating and set a $164.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, January 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $217.00 target price on shares of Sarepta Therapeutics in a report on Monday, November 26th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $147.00 target price for the company in a report on Tuesday, October 16th. Finally, Credit Suisse Group upped their target price on shares of Sarepta Therapeutics from $178.00 to $189.00 in a report on Thursday, October 4th. Four research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $182.32.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Further Reading: What Does Beta Mean In Stock Selection
Receive News & Ratings for Sarepta Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.